CLINICAL TRIAL article
Front. Nutr.
Sec. Clinical Nutrition
This article is part of the Research TopicFunctional Foods for Metabolic Health - Volume IIView all 3 articles
Potential lipid-lowering effects of Coffea arabica pulp extract product in hyperlipidemia-obese subjects: A randomized double-blind placebo-controlled trial
Provisionally accepted
Supawan Buranapin1*
Atcharaporn Ontawong2
Chutima S. Vaddhanaphuti1
Piti Inthaphan1
Jakkapong Inchai1
Thanthakan Saithong1Kanjana Narkprasom3Varunya Fuangchoom3Doungporn Amonlerdpison3- 1Chiang Mai University, Chiang Mai, Thailand
- 2University of Phayao, Mueang Phayao District, Thailand
- 3Maejo University, Nong Han, Thailand
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Coffea arabica pulp aqueous extract (CPE) exhibits anti-hyperlipidemia, anti-hyperglycemia, and anti-inflammatory effects in vitro and in vivo. This randomized, double-blind, controlled study evaluated the lipid-lowering effects of CPE product in hyperlipemia-obese participants. Methods: Seventy-nine obese men and women (BMI ≥ 25 kg/m2 and low-density lipoprotein cholesterol (LDL-C) ≥ 130 mg/dL) were randomly allocated to CPE product and control groups. CPE product or placebo were consumed twice daily for 24 weeks. The lipid profiles, BW, BMI, fat mass, and diabetic diagnosis parameters were assessed alongside adverse events measurements. Results: Within-group analysis showed a significant reduction of LDL-C, triglyceride (TG), and total cholesterol (TC) levels by 14.9%, 18.9%, and 8.0%, respectively, while increasing high-density lipoprotein cholesterol (HDL-C) levels by 6.0% in the CPE product group compared to baseline after 24 weeks of intervention. In the placebo group, LDL-C and HDL-C levels decreased significantly by 7.7% and 5.3%, respectively, at week 24, but TC and TG levels did not change significantly. After adjustment for screening lipid values, the CPE group showed greater reductions in total cholesterol, triglycerides, and LDL-C than the placebo group (−6.3% vs. −2.4%, p = 0.048; −12.5% vs. +1.17%, p = 0.078; and −13.7% vs. −7.1%, p = 0.01, respectively). HDL-C increased in the CPE group but decreased in the placebo group after adjustment (+7.1% vs. −5.0%, p < 0.0001). The adverse events were not different between the experimental groups. Conclusion: This study suggests that CPE product could be nutraceutical product option for lowering lipids in hyperlipidemic patients. However, this study has limitations, including the short treatment period, the small number of enrolled participants, and its exploratory nature. This study was registered at Thai Clinical Trial Registry as identification number 20241117005.
Keywords: Coffee pulp aqueous extract, CPE product, Hyperlipidemia, Lipid profiles, obese
Received: 26 Nov 2025; Accepted: 09 Feb 2026.
Copyright: © 2026 Buranapin, Ontawong, Vaddhanaphuti, Inthaphan, Inchai, Saithong, Narkprasom, Fuangchoom and Amonlerdpison. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Supawan Buranapin
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.